Genzyme Offers Upbeat Forecast
Updated from 11:31 a.m. EDT
Genzyme (GENZ) blew past earnings estimates for the second quarter, expanded its gross margins and increased its guidance, sending the biotech company's shares higher Thursday.
Genzyme earned $123.6 million, or 46 cents a share, in the quarter compared with $78.2 million, or 33 cents a share, a year ago. Excluding amortization and the effect of convertible debt, the company earned $149 million, or 57 cents a share. Analysts estimated a profit of 53 cents a share.
Revenue increased 22% to $668.1 million from $549.6 million. Shares of Genzyme were up $3.82, or 6.2%, to $65.15."We had a tremendous quarter, with strong revenue growth, continued expansion of the gross margin, solid cash flow, and earnings growth that exceeded our expectations," Henri A. Termeer, Genzyme's chairman and CEO, said in a press release. For the quarter, Genzyme's gross margin was 78% of revenue, up from 74% a year ago, thanks to improved margins for Renagel, Synvisc and enzyme replacement products, along with its exit from the generic cyclosporine business. For the third quarter, Genzyme expects earnings of 45 cents to 47 cents a share, or 55 cents to 57 cents a share before items. The company increased its revenue guidance for the year to between $2.6 billion and $2.8 billion from a range of $2.5 billion to $2.7 billion. Genzyme raised its full-year GAAP earnings per share guidance to a range of $1.75 to $1.80 from $1.72 to $1.78. The company lifted its profit forecast to between $2.20 and $2.25 excluding items, which follows a previous upward adjustment in its outlook. Estimated earnings before items exclude amortization and in-process research and development costs of 45 cents a share for the year and amortization expenses of 10 cents a share for the third quarter. Genzyme's performance was the result of major investments over a long period of time, Termeer said during a conference call Thursday. The company has been working toward sustainable growth by increasing production capabilities and sales, he said, but not all businesses are contributing as much. Genzyme plans to further develop its newer oncology, renal and bone care divisions.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV